Positive immunostaining with MLuC1 of bone marrow aspirate predicts poor outcome in patients with small-cell lung cancer

F. Pasini, G. Pelosi, G. Verlato, G. Guidi, F. Pavanel, D. Tummarello, A. Masotti, G. L. Cetto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Immunocytochemistry has been proven able to identify tumor cells in bone marrow aspirate (BMA) of patients with SCLC. However, few data exist about the clinical significance of the procedure. Patients and methods: 108 BMA taken from 60 patients were incubated with the MoAb MLuCl (cluster 6) and stained by the APAAP (alkaline phosphatase-antialkaline phosphatase) method. The serum levels of LDH, TPA, NSE and CEA were also studied in relation to bone marrow involvement by means of discriminant analysis. Results.' Immunocytochemistry of the aspirate with MLuC1 detected positive cells in 23 patients (38%) (38 of 108 samples) vs. 13% of the conventional biopsies studied without MLuCl (P <0.001). With respect to bone marrow positivity, three groups of patients were identified: those with no positive cells in the aspirate and negative biopsy (group A); those with less than 10 positive cells in the aspirate and negative biopsy (group B); and those with more than 10 positive cells or clumps in the aspirate or positive biopsy (group c). Group C patients had poorer median survivals than those in the other two groups (5.5 vs. 11 months, respectively, P = 0.01). Discriminant analysis showed that the four serum markers were poor discriminators of the degree of bone marrow involvement, with only 55% of grouped cases being correctly classified. Conclusions: These results show that detection of bone marrow involvement i) can be improved by the use of MLuCl ii) is not predictable by conventional tumor markers, and iii) is related to poor outcome.

Original languageEnglish
Pages (from-to)181-185
Number of pages5
JournalAnnals of Oncology
Volume9
Issue number2
DOIs
Publication statusPublished - Feb 1998

Fingerprint

Small Cell Lung Carcinoma
Bone Marrow
Biopsy
Discriminant Analysis
Immunohistochemistry
Tumor Biomarkers
Phosphoric Monoester Hydrolases
Bone Marrow Cells
Alkaline Phosphatase
Biomarkers
Survival
Serum
Neoplasms

Keywords

  • Bone marrow
  • Monoclonal antibodies
  • Small-cell lung cancer
  • Survival
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Positive immunostaining with MLuC1 of bone marrow aspirate predicts poor outcome in patients with small-cell lung cancer. / Pasini, F.; Pelosi, G.; Verlato, G.; Guidi, G.; Pavanel, F.; Tummarello, D.; Masotti, A.; Cetto, G. L.

In: Annals of Oncology, Vol. 9, No. 2, 02.1998, p. 181-185.

Research output: Contribution to journalArticle

Pasini, F. ; Pelosi, G. ; Verlato, G. ; Guidi, G. ; Pavanel, F. ; Tummarello, D. ; Masotti, A. ; Cetto, G. L. / Positive immunostaining with MLuC1 of bone marrow aspirate predicts poor outcome in patients with small-cell lung cancer. In: Annals of Oncology. 1998 ; Vol. 9, No. 2. pp. 181-185.
@article{ff26bdfaa92e473f85385d77cdd0ff68,
title = "Positive immunostaining with MLuC1 of bone marrow aspirate predicts poor outcome in patients with small-cell lung cancer",
abstract = "Background: Immunocytochemistry has been proven able to identify tumor cells in bone marrow aspirate (BMA) of patients with SCLC. However, few data exist about the clinical significance of the procedure. Patients and methods: 108 BMA taken from 60 patients were incubated with the MoAb MLuCl (cluster 6) and stained by the APAAP (alkaline phosphatase-antialkaline phosphatase) method. The serum levels of LDH, TPA, NSE and CEA were also studied in relation to bone marrow involvement by means of discriminant analysis. Results.' Immunocytochemistry of the aspirate with MLuC1 detected positive cells in 23 patients (38{\%}) (38 of 108 samples) vs. 13{\%} of the conventional biopsies studied without MLuCl (P <0.001). With respect to bone marrow positivity, three groups of patients were identified: those with no positive cells in the aspirate and negative biopsy (group A); those with less than 10 positive cells in the aspirate and negative biopsy (group B); and those with more than 10 positive cells or clumps in the aspirate or positive biopsy (group c). Group C patients had poorer median survivals than those in the other two groups (5.5 vs. 11 months, respectively, P = 0.01). Discriminant analysis showed that the four serum markers were poor discriminators of the degree of bone marrow involvement, with only 55{\%} of grouped cases being correctly classified. Conclusions: These results show that detection of bone marrow involvement i) can be improved by the use of MLuCl ii) is not predictable by conventional tumor markers, and iii) is related to poor outcome.",
keywords = "Bone marrow, Monoclonal antibodies, Small-cell lung cancer, Survival, Tumor markers",
author = "F. Pasini and G. Pelosi and G. Verlato and G. Guidi and F. Pavanel and D. Tummarello and A. Masotti and Cetto, {G. L.}",
year = "1998",
month = "2",
doi = "10.1023/A:1008226025229",
language = "English",
volume = "9",
pages = "181--185",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Positive immunostaining with MLuC1 of bone marrow aspirate predicts poor outcome in patients with small-cell lung cancer

AU - Pasini, F.

AU - Pelosi, G.

AU - Verlato, G.

AU - Guidi, G.

AU - Pavanel, F.

AU - Tummarello, D.

AU - Masotti, A.

AU - Cetto, G. L.

PY - 1998/2

Y1 - 1998/2

N2 - Background: Immunocytochemistry has been proven able to identify tumor cells in bone marrow aspirate (BMA) of patients with SCLC. However, few data exist about the clinical significance of the procedure. Patients and methods: 108 BMA taken from 60 patients were incubated with the MoAb MLuCl (cluster 6) and stained by the APAAP (alkaline phosphatase-antialkaline phosphatase) method. The serum levels of LDH, TPA, NSE and CEA were also studied in relation to bone marrow involvement by means of discriminant analysis. Results.' Immunocytochemistry of the aspirate with MLuC1 detected positive cells in 23 patients (38%) (38 of 108 samples) vs. 13% of the conventional biopsies studied without MLuCl (P <0.001). With respect to bone marrow positivity, three groups of patients were identified: those with no positive cells in the aspirate and negative biopsy (group A); those with less than 10 positive cells in the aspirate and negative biopsy (group B); and those with more than 10 positive cells or clumps in the aspirate or positive biopsy (group c). Group C patients had poorer median survivals than those in the other two groups (5.5 vs. 11 months, respectively, P = 0.01). Discriminant analysis showed that the four serum markers were poor discriminators of the degree of bone marrow involvement, with only 55% of grouped cases being correctly classified. Conclusions: These results show that detection of bone marrow involvement i) can be improved by the use of MLuCl ii) is not predictable by conventional tumor markers, and iii) is related to poor outcome.

AB - Background: Immunocytochemistry has been proven able to identify tumor cells in bone marrow aspirate (BMA) of patients with SCLC. However, few data exist about the clinical significance of the procedure. Patients and methods: 108 BMA taken from 60 patients were incubated with the MoAb MLuCl (cluster 6) and stained by the APAAP (alkaline phosphatase-antialkaline phosphatase) method. The serum levels of LDH, TPA, NSE and CEA were also studied in relation to bone marrow involvement by means of discriminant analysis. Results.' Immunocytochemistry of the aspirate with MLuC1 detected positive cells in 23 patients (38%) (38 of 108 samples) vs. 13% of the conventional biopsies studied without MLuCl (P <0.001). With respect to bone marrow positivity, three groups of patients were identified: those with no positive cells in the aspirate and negative biopsy (group A); those with less than 10 positive cells in the aspirate and negative biopsy (group B); and those with more than 10 positive cells or clumps in the aspirate or positive biopsy (group c). Group C patients had poorer median survivals than those in the other two groups (5.5 vs. 11 months, respectively, P = 0.01). Discriminant analysis showed that the four serum markers were poor discriminators of the degree of bone marrow involvement, with only 55% of grouped cases being correctly classified. Conclusions: These results show that detection of bone marrow involvement i) can be improved by the use of MLuCl ii) is not predictable by conventional tumor markers, and iii) is related to poor outcome.

KW - Bone marrow

KW - Monoclonal antibodies

KW - Small-cell lung cancer

KW - Survival

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0031939342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031939342&partnerID=8YFLogxK

U2 - 10.1023/A:1008226025229

DO - 10.1023/A:1008226025229

M3 - Article

VL - 9

SP - 181

EP - 185

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -